Size : | Price | Quantity | |
---|---|---|---|
5 mg | $68.00 | ||
25 mg | $272.00 |
SRPIN340 (218156-96-8) is a selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki = 0.89 μM).1 Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Inhibits viral replication by inhibition of host SR protein kinases.1 SRPIN340 modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy2 and controls VEGF-mediated tumor angiogenesis in xenografts3.
References/Citations:
1) Fukuhara et al. (2006), Utilization of host SR protein kinases and RNA-splicing machinery during viral replication; Proc. Natl. Acad. Sci. USA, 103 11329
2) Gammons et al. (2013), SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity; Invest. Ophthalmol. Vis. Sci., 54 5797
3) Gammons et al. (2014), Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma; Br. J. Cancer, 111 477
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SRPIN340 (218156-96-8) is a selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki = 0.89 μM).1 Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Inhibits viral replication by inhibition of host SR protein kinases.1 SRPIN340 modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy2 and controls VEGF-mediated tumor angiogenesis in xenografts3.
References/Citations:
1) Fukuhara et al. (2006), Utilization of host SR protein kinases and RNA-splicing machinery during viral replication; Proc. Natl. Acad. Sci. USA, 103 11329
2) Gammons et al. (2013), SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity; Invest. Ophthalmol. Vis. Sci., 54 5797
3) Gammons et al. (2014), Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma; Br. J. Cancer, 111 477
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.